Similar articles

• Two new drugs for renal cell carcinoma.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2007 Feb 26;49(1255):18-20. Med Lett Drugs Ther. 2007. PMID: 17325624 No abstract available.
• Kidney cancer: Does hypothyroidism predict clinical outcome?

  Rini B. Rini B. Nat Rev Urol. 2011 Jan;8(1):10-1. doi: 10.1038/nrurol.2010.191. Epub 2010 Nov 30. Nat Rev Urol. 2011. PMID: 21116300 No abstract available.
• [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].

  Kondo T. Kondo T. Nihon Jinzo Gakkai Shi. 2012;54(5):574-80. Nihon Jinzo Gakkai Shi. 2012. PMID: 22991835 Review. Japanese. No abstract available.
• Newly approved therapies for RCC and their effect on the standard of care.

  Figlin RA. Figlin RA. Clin Adv Hematol Oncol. 2007 Jan;5(1):35-6, 66. Clin Adv Hematol Oncol. 2007. PMID: 17339824 No abstract available.
• CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.

  Stein MN, Flaherty KT. Stein MN, et al. Clin Cancer Res. 2007 Jul 1;13(13):3765-70. doi: 10.1158/1078-0432.CCR-06-2844. Clin Cancer Res. 2007. PMID: 17606705 Review. No abstract available.